Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9994503 | 0.86 | GRM5 (0.41) | — | |
| SCHEMBL6922655 | 0.83 | LMNA (0.39) | RAB9ASMN1; SMN2NPC1LMNACYP2C19 | |
| SCHEMBL6922292 | 0.81 | RAB9A (0.38) | RAB9ASMN1; SMN2TGFBR1NPC1LMNA | |
| SCHEMBL6921810 | 0.79 | HDAC3 (0.35) | RAB9ASMN1; SMN2NPC1CTSDOTUD7B | |
| SCHEMBL6921870 | 0.78 | RAB9A (0.40) | RAB9ASMN1; SMN2NPC1LMNACYP2C19 | |
| SCHEMBL6920401 | 0.77 | USP2 (0.38) | CYP2C19BCL2A1CYP1A2CYP3A4OTUD7B | |
| SCHEMBL6921643 | 0.76 | MEN1 (0.57) | RAB9ASMN1; SMN2NPC1LMNACYP2C19 | |
| SCHEMBL6920781 | 0.76 | LMNA (0.48) | RAB9ASMN1; SMN2NPC1LMNACYP2C19 | |
| SCHEMBL12059068 | 0.76 | LMNA (0.50) | RAB9ASMN1; SMN2NPC1LMNACYP2C19 | |
| SCHEMBL6923330 | 0.75 | KDM4E (0.58) | RAB9ASMN1; SMN2NPC1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | RAB9A 1387/4885SMN1; SMN2 636/4885TGFBR1 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.